Eikon Therapeutics (EIKN) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.59

Estimate

-$1.66

Surprise

+4.0%

Score today

4.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Eikon Therapeutics (EIKN) reported a narrower loss than forecast — adjusted EPS of -$1.59 against the -$1.66 estimate (a 4.0% beat on a still-unprofitable quarter).

• Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Program Updates — fiscal.ai, 2026-11-12
• Eikon Therapeutics Q3 EPS $(1.59) Beats $(1.68) Estimate — benzinga, 2026-11-12
• 12 Health Care Stocks Moving In Tuesday's Pre-Market Session — benzinga, 2026-11-10

TrendMatrix currently rates EIKN Hold at 4.9/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +4.0% surprise compares with a -36.4% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$6.04

Price target

$8.31

Stop

$5.62

Upside to target

+37.6%

Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$327.2M

P/E (fwd)

-0.9

52-week range

$5.01–$17.40

Off 52-week high

65.3%

RSI (14)

39

Volume vs avg

1.33×

Score today

4.9/10